News of Note—Sarepta, Verastem and Voyager clock data win, shares boost

Positive data day for three biotechs

> Sarepta Therapeutics saw its shares jump 13% in early morning trading on new phase 1/2 data from its next-gen DMD candidate golodirsen. The medication hit its primary and secondary endpoints in 25 boys with confirmed deletions of the DMD gene, amenable to skipping exon 53, by boosting mean dystrophin protein by just over 1%, as well as increasing dystrophin immunofluorescence. It now plots an accelerated review with the FDA. Statement.

> Verastem said its medication duvelisib, bought up from struggling Infinity Pharmaceuticals late last year, has seen some positive data, coming after its previous owner last year posted results showing it had hit its primary endpoint in a phase 2 for indolent non-Hodgkin lymphoma, but fell short of expectations. The latest phase 3 readout from Verastem showed it could boost progression-free survival in chronic lymphocytic leukemia/small lymphocytic lymphoma compared to Novartis’ Arzerra. Its shares shot up by 35% this morning. Release.

> Voyager Therapeutics said its ongoing Phase 1b trial of its gene therapy VY-AADC01 in advanced Parkinson’s disease is showing “improvements across multiple measures of patients’ motor function after a one-time administration of the gene therapy.” It, too, saw its stock rise, up around 20% this morning. Statement.


Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

Suggested Articles

Pfizer licensed the drugs, gamma secretase inhibitor nirogacestat and MEK inhibitor mirdametinib, to SpringWorks in 2017.

The company, which was co-founded by Jim Mellon, has reeled in $165 million in 18 months to establish itself at the forefront of the longevity field.

The FDA broadened its approval of Medtronic’s transcatheter aortic valve replacement to include patients at a low risk of surgical complications.